| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872838 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Aug, 2018
(5 years ago) | |
| US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(1 year, 9 months ago) | |
Lusedra is owned by Eisai Inc.
Lusedra contains Fospropofol Disodium.
Lusedra has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lusedra are:
- US6872838
- US6204257
Lusedra was authorised for market use on 12 December, 2008.
Lusedra is available in solution;intravenous dosage forms.
Lusedra can be used as sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation.
Drug patent challenges can be filed against Lusedra from 12 December, 2012.
The generics of Lusedra are possible to be released after 01 July, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2013 |
Drugs and Companies using
FOSPROPOFOL DISODIUM ingredient
NCE-1 date:
12 December, 2012
Market Authorisation Date:
12 December, 2008Treatment:
Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedationDosage:
SOLUTION;INTRAVENOUS
More Information on Dosage
LUSEDRA family patents
